Multicenter, international, retrospective study of prognostic factors for Ra223
Abstract The risk factors for adium-233 dichloride (Ra223) treatment on prognosis remain unclear. We aimed to validate the risk model for a radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC). We retrospectively evaluated 345 patien...
Saved in:
| Main Authors: | Takuya Oishi, Hao-Lun Luo, Yoshiomi Hatayama, Hideo Kawaguchi, Daichi Sasaki, Ryuma Tanaka, Noriaki Ishii, Jotaro Mikami, Teppei Okamoto, Hayato Yamamoto, Masahiko Aoki, Yu-Li Su, Yen-Hao Chen, Yen-Hsiang Chang, Yen-Ta Chen, Hung-Jen Wang, Chikara Ohyama, Shingo Hatakeyama |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-95844-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01) -
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Colleen Mackenzie, et al.
Published: (2024-10-01) -
Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer
by: O. I. Kit, et al.
Published: (2024-12-01) -
Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
by: John Buscombe, et al.
Published: (2021-04-01) -
Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges
by: Amit Bhoil, et al.
Published: (2022-12-01)